Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (GB:0K1R)
LSE:0K1R
RESEARCH TOOLSreports
Viridian Therapeutics (0K1R) Share Price & Analysis
0 Followers
0K1R Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.98 - $28.00
Previous Close$12.88
Volume3.68K
Average Volume (3M)659.00
Market Cap
$808.45M
Enterprise Value$627.04M
Total Cash (Recent Filing)$201.41M
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)-2.4
Beta0.62
Next Earnings
May 08, 2024EPS Estimate
-$1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.32
Shares Outstanding62,767,570
10 Day Avg. Volume0
30 Day Avg. Volume659
Standard Deviation0.37
R-Squared0.00431
Alpha-0.00882
Financial Highlights & Ratios
Price to Book (P/B)2.22
Price to Sales (P/S)607.42
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.52K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.68
Forecast
1Y Price Target
$36.82Price Target Upside185.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Viridian Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial Strategy And Growth PotentialAnalyst maintains an Outperform rating on VRDN with a new target of $40, reflecting confidence in the company's financial strategy and growth potential.
Product Development MilestoneVRDN's nomination of VRDN-003 to be advanced as a subcutaneous product for Thyroid Eye Disease marks an important milestone.
Upcoming Data ReleaseAnticipated mid-2024, THRIVE pivotal data for Viridian Therapeutics' VRDN-001 could potentially bring positive developments.
Bears Say
Competitor ProgressWith competitor Amgen advancing their own subcutaneous Tepezza program, there is increased pressure on VRDN to execute effectively in a competitive market.
Financial ResultsLast quarter, Viridian reported earnings per share of -$1.35 versus the consensus of -$0.99 and the estimate of -$0.91, primarily due to severance costs for its outgoing CEO.
Market SentimentViridian's stock is faced with a high short interest, indicating that a significant portion of the market may be betting against the company's success.
---
Options Prices
Currently, No data available
---
Ownership Overview
36.25% Insiders
23.10% Mutual Funds
18.03% Other Institutional Investors
22.62% Public Companies and
Individual Investors
0K1R FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest share price was $10.98 and its highest was $28.00 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Currently, no data Available
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is May 08, 2024 which is in 9 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Mar 13, 2024. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$0.978 by -$0.372.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -$1.09.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 62,767,570 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1.35 in its last earnings report, missing expectations of -$0.978. Following the earnings report the stock price went down -3.144%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Among the largest hedge funds holding Viridian Therapeutics’s share is Maverick Capital ltd. It holds Viridian Therapeutics’s shares valued at 51M.
---
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.82 (185.78% Upside)
$36.82 (185.78% Upside)
Blogger Sentiment
Bullish
GB:0K1R Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.38%
12-Months-Change
Fundamentals
Return on Equity
-56.80%
Trailing 12-Months
Asset Growth
12.72%
Trailing 12-Months
Company Description
Viridian Therapeutics
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
---
0K1R Company Deck
---
0K1R Earnings Call
Q1 2023
0:00 / 0:00
---
0K1R Stock 12 Months Forecast
Average Price Target
$36.82
▲(185.78% Upside)
Technical Analysis
Viridian Therapeutics
―
Voyager Therapeutics
―
Kura Oncology
―
Arrowhead Pharmaceuticals
―
Protagonist Therapeutics
―
Best Analysts Covering 0K1R
1 Year
1 Year Success Rate
7/20 ratings generated profit
1 Year Average Return
-6.14%
reiterated a buy rating 2 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of -6.14% per trade.
---